Welcome to IntegraGen's News and Events page. Here you will find current and archived press releases, listings of upcoming events, and news coverage about the company and some of its projects and initiatives.

Contact us if you would like more information about IntegraGen and our efforts.

IntegraGen Reports Results for 1st Half of 2020

IntegraGen has announced today its financial results for the first half of 2020 with the accounts having been reviewed by the Board of Directors on 17 September 2020.

Company posts positive operating performance (EBITDA) for the second consecutive semester, supported by revenue growth (+5%) and  confirms (…)  » 

COMBINED GENERAL ASSEMBLY

integragen

IntegraGen’s Combined General Assembly for 2020 will be held on September 17, 2020 at 2 p.m. at the company’s headquarters which is located at Génopole Campus 1,Genavenir 8, Porte 840, 5 rue Henri Desbruères – 91000 Evry, France

Click here for more (…)  » 

Agreement to file a friendly takeover bid initiated by ONCODNA on INTEGRAGEN

Agreement to file a friendly takeover bid initiated by ONCODNA on INTEGRAGEN to acquire all outstanding shares at a price of 2.20€ per share. This transaction would bring together OncoDNA’s expertise in oncology precision medicine and IntegraGen’s know-how in DNA sequencing services and bioinformatics analyses. The combination of (…)  » 

What’s new with MERCURY?

Our latest release: MERCURY™ v3.0

We are excited to provide you with important information regarding the release of a new version (v3.0) of MERCURY™. This updated version of MERCURY has a number of changes and improvements designed to enhance data analysis capabilities and the user experience.

MERCURY v3.0 has (…)  » 

IntegraGen Achieves CE Mark for Its MERCURY™ Cloud-based Software Tool Which Supports Molecular Tumor Profiling for Cancer Patients

IntegraGen announces the company’s MERCURY cloud-based analytical software tool has achieved Conformité Européenne (CE) marking. This registration enhances the ability for IntegraGen sell MERCURY throughout the European Union (EU). MERCURY is utilized by researchers and clinicians to assist with the analysis of sequencing data derived from small (…)  » 

IntegraGen reports 2019 annual results

integragen

+20% sales growth, positive gross operating surplus during second half of year, and close to break-even for the year

IntegraGen announced its financial results for the year ending December 31, 2019. The annual accounts were approved by the Board of Directors at a meeting held on April 2, 2020.

Operating (…)  » 

IntegraGen Update – Still open to meet your research needs

IntegraGen is following the French Government’s recommendations and precautionary measures for COVID-19. As an essential supplier of genomic research services, we are committed to meeting the needs of our customers while also making every effort to protect the health and well-being of our employees and their families.

We have undertaken (…)  » 

IntegraGen announces leading U.S. cancer center to use MERCURY™ cloud-based tool for oncology sequencing data interpretation and reporting

IntegraGen today announced Dana-Farber Cancer Institute will utilize the company’s MERCURY™ cloud-based software as part of their analysis and reporting process for sequencing data obtained from tumors of cancer patients. Dana-Farber plans to utilize MERCURY to assist in the analysis of sequencing data obtained from small and large (…)  »